A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis

Conditions: Dermatitis Atopic Interventions: Drug: Amlitelimab; Drug: Placebo; Drug: Topical corticosteroids; Drug: Topical calcineurin inhibitors Sponsors: Sanofi Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials